Market Overview

UPDATE: Stifel Nicolaus Initiates Oncolytics Ciotech at Buy with $6 PT on Reolysin Cancer Focus

Share:
Related ONCY
Oncolytics Biotech Collaborators to Present Survival Data from REO 016 Study in NCLC at IASLC
US Stock Futures Signal Lower Start On Wall Street
Oncolytics' Reolysin Phase II Lung Cancer Study Enrolled (Zacks)

Stifel Nicolaus initiated its coverage on Oncolytics Ciotech (NASDAQ: ONCY) with a Buy rating and a price target of $6 a share.

Stifel Nicolaus commented, "We view ONCY's sole clinical candidate Reolysin as a compelling potential treatment for ~60% of cancers. Reolysin is a specific strain of a naturally occurring virus that only replicates in cancer cells with an activated Ras signaling pathway, a key metabolic pathway in cell metabolism that is mutated in over 60% of all carcinomas. Reolysin has demonstrated compelling efficacy in numerous oncology indications and as a live virus Reolysin's main side effect is "viral syndrome", not the typical side effects of chemotherapy."

Oncolytics Ciotech closed at $2.76 on Wednesday.

Latest Ratings for ONCY

DateFirmActionFromTo
Sep 2013NeedhamInitiates Coverage onBuy
Mar 2013Piper JaffrayInitiates Coverage onOverweight
Dec 2012Bloom Burton & Co.DowngradesBuyHold

View More Analyst Ratings for ONCY
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ONCY)

Get Benzinga's Newsletters